重庆口岸药品监督管理局将增设生物制品进口备案职能

2019-01-18 Kerr 新浪医药新闻

1月18日,国家药监局官网发布关于同意重庆口岸药品监督管理局增设生物制品进口备案职能的批复(国药监药注函〔2019〕9号)。全文如下:


1月18日,国家药监局官网发布关于同意重庆口岸药品监督管理局增设生物制品进口备案职能的批复(国药监药注函〔2019〕9号)。全文如下:

重庆市药品监督管理局:

你局《关于申请增设生物制品通关备案及进口检验功能的请示》(渝药监文〔2018〕10号)收悉。根据《国务院关于支持自由贸易试验区深化改革创新若干措施的通知》(国发﹝2018﹞38号)精神,以及《食品药品监管总局办公厅 海关总署办公厅关于印发增设允许药品进口口岸工作评估考核方案的通知》(食药监办药化管〔2015〕134号)有关规定,我局组织中国食品药品检定研究院对重庆市食品药品检验检测研究院进行了考核评估,基本符合口岸药品检验机构对生物制品进口检验的条件。经研究,现批复如下:

一、同意重庆口岸药品监督管理局增设生物制品进口备案职能。自本批复印发之日起,重庆口岸药品监督管理局可办理生物制品进口备案手续。

二、重庆市食品药品检验检测研究院负责进口生物制品的口岸检验工作。对目前重庆市食品药品检验检测研究院尚不具备检验能力的品种、项目以及按批签发管理的生物制品,可由重庆市食品药品检验检测研究院根据重庆市口岸药品监督管理局发出的《进口药品口岸检验通知书》抽取样品后,送中国食品药品检定研究院进行检验。重庆市口岸药品监督管理局凭中国食品药品检定研究院出具的检验报告办理进口备案手续。

三、你局和重庆市食品药品检验检测研究院应持续加强自身建设,不断提高管理能力和技术水平,保障药品进口管理工作的顺利开展。

国家药监局

2019年1月16日

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1683948, encodeId=6bfa168394829, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Feb 14 15:31:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476251, encodeId=09e314e625136, content=<a href='/topic/show?id=ae0669226c3' target=_blank style='color:#2F92EE;'>#生物制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69226, encryptionId=ae0669226c3, topicName=生物制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd657261208, createdName=楚钟, createdTime=Sun Jan 20 11:31:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590960, encodeId=5f361590960a2, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Jan 20 11:31:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-02-14 zxl738
  2. [GetPortalCommentsPageByObjectIdResponse(id=1683948, encodeId=6bfa168394829, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Feb 14 15:31:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476251, encodeId=09e314e625136, content=<a href='/topic/show?id=ae0669226c3' target=_blank style='color:#2F92EE;'>#生物制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69226, encryptionId=ae0669226c3, topicName=生物制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd657261208, createdName=楚钟, createdTime=Sun Jan 20 11:31:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590960, encodeId=5f361590960a2, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Jan 20 11:31:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1683948, encodeId=6bfa168394829, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Feb 14 15:31:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476251, encodeId=09e314e625136, content=<a href='/topic/show?id=ae0669226c3' target=_blank style='color:#2F92EE;'>#生物制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69226, encryptionId=ae0669226c3, topicName=生物制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd657261208, createdName=楚钟, createdTime=Sun Jan 20 11:31:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590960, encodeId=5f361590960a2, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Jan 20 11:31:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-20 cenghis